2-氨基-5-(甲基磺酰基)-4-苯基-1,3-噻唑 | 1000018-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氨基-5-(甲基磺酰基)-4-苯基-1,3-噻唑
• 英文名称: 2-Amino-5-methylsulfonyl-4-phenyl-1,3-thiazole
• 英文别名: 5-methylsulfonyl-4-phenyl-1,3-thiazol-2-amine
• CAS: 1000018-51-8
• 化学式: C₁₀H₁₀N₂O₂S₂
• 分子量: 254.334
• InChiKey: MENYNNGOWMJUEG-UHFFFAOYSA-N

物化性质

• 沸点：
  541.1±42.0 °C(Predicted)
• 密度：
  1.401±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  (3,3-diphenyl-propyl)-(2-morpholin-4-yl-ethyl)-amine 、 2-氨基-5-(甲基磺酰基)-4-苯基-1,3-噻唑 、 N,N'-羰基二咪唑 在 4-二甲氨基吡啶 作用下， 反应 60.0h， 生成 1-(3,3-Diphenylpropyl)-3-(5-methylsulfonyl-4-phenyl-1,3-thiazol-2-yl)-1-(2-morpholin-4-ylethyl)urea
  参考文献：
  名称：

  Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism

  摘要：

  A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essential to finding a compound suitable for oral dosing. Calcimimetic 18 exhibited excellent in vivo potency in a 5/6 nephrectomized rat model and cross-species pharmacokinetics. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.050

文献信息

• Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism
  作者：Paul M. Wehn、Paul E. Harrington、Timothy J. Carlson、James Davis、Pierre Deprez、Christopher H. Fotsch、Mark P. Grillo、Jenny Ying-Lin Lu、Sean Morony、Kanaka Pattabiraman、Steve F. Poon、Jeff D. Reagan、David J. St. Jean、Taoues Temal、Minghan Wang、Yuhua Yang、Charles Henley、Sarah E. Lively

  DOI：10.1016/j.bmcl.2013.10.050

  日期：2013.12

  A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essential to finding a compound suitable for oral dosing. Calcimimetic 18 exhibited excellent in vivo potency in a 5/6 nephrectomized rat model and cross-species pharmacokinetics. (C) 2013 Elsevier Ltd. All rights reserved.